S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NYSE:TARO

Taro Pharmaceutical Industries Earnings Date, Estimates, & History

$63.99
+0.19 (+0.30 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$63.28
$64.27
50-Day Range
$62.34
$73.38
52-Week Range
$53.95
$80.00
Volume16,129 shs
Average Volume24,402 shs
Market Capitalization$2.43 billion
P/E Ratio84.20
Dividend YieldN/A
Beta0.93

Earnings Summary

Upcoming
Earnings Date
Oct. 27
Estimated

Actual EPS
(Jul. 27)
$1.09
Beat By $0.25

Consensus EPS
(Jul. 27)
$0.84

Last Year's Q3 EPS
(7/29/2020)
-$11.37

Taro Pharmaceutical Industries Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Taro Pharmaceutical Industries Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taro Pharmaceutical Industries (NYSE:TARO) Earnings Estimates

Current Year EPS Consensus Estimate: $4.21 EPS
Next Year EPS Consensus Estimate: $4.55 EPS

TARO Earnings Information

Taro Pharmaceutical Industries last posted its earnings data on July 27th, 2021. The reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.25. The business had revenue of $147.11 million for the quarter, compared to analyst estimates of $137.20 million. Taro Pharmaceutical Industries has generated $3.70 earnings per share over the last year ($0.76 diluted earnings per share) and currently has a price-to-earnings ratio of 84.2. Earnings for Taro Pharmaceutical Industries are expected to grow by 8.08% in the coming year, from $4.21 to $4.55 per share. Taro Pharmaceutical Industries has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 27th, 2021 based off prior year's report dates.

Taro Pharmaceutical Industries (NYSE:TARO) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
10/27/2021
(Estimated)
        
7/27/20216/30/2021$0.84$1.09+$0.25$2.68$137.20 million$147.11 million
5/18/2021Q4$0.92($0.78)($1.70)$2.40$147.33 million$148.35 million
1/27/202112/31/2020$1.01$0.86($0.15)$0.86$152.63 million$140.15 million
10/28/20209/30/2020$0.77$1.18+$0.41$1.18$125.30 million$142.84 million  
7/29/20206/30/2020$1.16($11.37)($12.53)$12.89$158.35 million$117.63 million
5/19/20203/31/2020$1.53$1.42($0.11)$1.42$168.25 million$174.94 million  
2/3/2020Q3$1.54$1.76+$0.22$1.76$172.00 million$147.68 million
11/4/2019Q2$1.72$1.46($0.26)$1.46$168.60 million$160.85 million  
8/8/2019Q1$1.96$1.72($0.24)$1.72$169.80 million$161.30 million
5/22/2019Q4$2.26$1.52($0.74)$1.52$189.90 million$179.92 million  
2/6/2019Q3 2019$1.95$2.40+$0.45$2.40$174.70 million$176.38 million
11/5/20189/30/2018$1.96$1.60($0.36)$1.60$167.40 million$158.97 million
8/9/20186/30/2018$2.33$1.71($0.62)$1.71$179.54 million$154.62 million
5/17/20183/31/2018$1.51$2.17+$0.66$2.17$166.59 million$175.22 million  
2/7/2018Q3 2018$1.37+$1.37$2.29$155.46 million
11/7/2017Q2 2018$1.30+$1.30$1.30$169.92 million
8/8/2017Q1 2018$1.35+$1.35$1.35$161.32 million
5/22/2017Q4$2.05+$2.05$2.05$196.41 million
2/9/2017Q3 2017$3.42+$3.42$3.42$220.40 million
11/8/2016Q2 2017$3.00+$3.00$3.00$228.79 million  
8/10/2016Q1 2017$2.59+$2.59$2.59$215.30 million$233.80 million
5/26/2016Q4 2016$2.68+$2.68$2.68$265.07 million  
2/10/2016Q3 2016$4.41+$4.41$4.41$974.38 million$258.30 million
11/3/2015Q2 2016$3.11+$3.11$3.11$212.06 million
8/6/2015Q1 2016$2.42+$2.42$2.42$1.01 billion$215.30 million
5/26/2015Q4 2015$3.56+$3.56$3.56$881.79 million$244.18 million  
2/10/2015Q3 2015$3.33+$3.33$3.33$213.60 million$237.70 million
11/9/2014Q2 2015$3.35+$3.35$3.35$250.83 million
8/7/2014Q1 2015$0.98+$0.98$0.88$130.23 million
5/27/2014Q4 2014$2.10+$2.10$2.10$165.13 million$187.20 million
2/10/2014Q3 2014$2.59+$2.59$2.59$185.70 million$213.60 million
11/12/2013Q2 2014$2.15+$2.15$2.15$205.32 million
8/7/2013Q1 2014$1.32+$1.32$1.32$159.15 million$153.20 million
5/23/2013Q4 2013$1.45+$1.45$1.80$145.00 million$165.10 million
2/4/2013Q3 2013$1.98+$1.98$1.98
11/1/2012Q213$1.46+$1.46$138.25 million$160.97 million
8/6/2012Q1 2013$1.41+$1.41$1.41
5/24/2012Q4 2012$1.06+$1.06$1.06
2/10/2012Q3 2012$1.42+$1.42$1.44
11/10/2011Q2 2012$1.31+$1.31$1.30
7/26/2011Q1 2012$0.81+$0.81$0.82
5/26/2011Q4 2011$0.58+$0.58$0.58
1/28/2011Q3 2011$0.11+$0.11$0.11
10/29/2010Q2 2011$0.46+$0.46$0.46
8/23/2010Q1 2011$0.46+$0.46$0.46
6/14/2010Q4 2010$0.25+$0.25$0.25
12/2/2009Q2 2010$0.24+$0.24$0.24
8/10/2009Q1 2010$0.31+$0.31$0.31
5/22/2009Q4 2009$0.27+$0.27$0.27
2/10/2009Q3 2009$0.65+$0.65$0.85
11/11/2008Q2 2009$0.31+$0.31$0.31
(Earnings results data provided by Zacks Investment Research)
speech bubbles
speech bubbles











Taro Pharmaceutical Industries (NYSE:TARO) Earnings Frequently Asked Questions

When is Taro Pharmaceutical Industries's earnings date?

Taro Pharmaceutical Industries has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 27th, 2021 based off last year's report dates. Learn more on TARO's earnings history

Did Taro Pharmaceutical Industries beat their earnings estimates last quarter?

In the previous quarter, Taro Pharmaceutical Industries (NYSE:TARO) reported $1.09 earnings per share (EPS) to beat the analysts' consensus estimate of $0.84 by $0.25. Learn more on TARO's earnings details

How much revenue does Taro Pharmaceutical Industries generate each year?

Taro Pharmaceutical Industries (NYSE:TARO) has a recorded annual revenue of $548.97 million.

How much profit does Taro Pharmaceutical Industries generate each year?

Taro Pharmaceutical Industries (NYSE:TARO) has a recorded net income of -$386.65 million. TARO has generated $3.70 earnings per share over the last four quarters.

What is Taro Pharmaceutical Industries's price-to-earnings ratio?

Taro Pharmaceutical Industries (NYSE:TARO) has a trailing price-to-earnings ratio of 84.20 and a forward price-to-earnings ratio of 15.20.

What is Taro Pharmaceutical Industries's EPS forecast for next year?

Taro Pharmaceutical Industries's earnings are expected to grow from $4.21 per share to $4.55 per share in the next year, which is a 8.08% increase.

This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.